CLSA has released a research report stating that Pharmaron (03759, 300759.SZ) has revised its 2025 revenue growth guidance from 10%-15% year-on-year to 12%-16%, with adjusted non-IFRS net profit expected to achieve double-digit growth. The firm views the upward revision of guidance and increased backlog as positive indicators for the fourth quarter of this year through next year. CLSA has raised its revenue and net profit forecasts for Pharmaron from 2025 to 2027, increasing the H-share target price from HK$24.7 to HK$28.8 and the A-share target price from RMB 34.8 to RMB 40.6, maintaining an "Outperform" rating for both.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.